(Q37810305)

23 August 2017

title

Clinical experience of QuantiFERON(®) -TB Gold testing in patients with psoriasis treated with tumour necrosis factor blockers in Taiwan (English)

1 reference

23 August 2017

0 references

H-Y Chiu

1

1 reference

23 August 2017

P-R Hsueh

series ordinal

2

1 reference

23 August 2017

T-F Tsai

series ordinal

3

1 reference

23 August 2017

language of work or name

English

0 references

publication date

17 February 2011

1 reference

British Journal of Dermatology

23 August 2017

published in

1 reference

23 August 2017

volume

164

1 reference

23 August 2017

issue

3

1 reference

23 August 2017

page(s)

553-559

1 reference

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2010.10137.X

Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2010.10137.X

Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2010.10137.X

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2010.10137.X

Effectiveness of the combination of a whole-blood interferon-gamma assay and the tuberculin skin test in detecting latent tuberculosis infection in rheumatoid arthritis patients receiving adalimumab therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2010.10137.X

Specific detection of tuberculosis infection: an interferon-gamma-based assay using new antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2010.10137.X

Biological therapies in the systemic management of psoriasis: International Consensus Conference

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2010.10137.X

Comparison of the sensitivity and specificity of two whole blood interferon-gamma assays for M. tuberculosis infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2010.10137.X

Tuberculosis and tumour necrosis factor-alpha inhibitor therapy: a report of three cases in patients with psoriasis. Comprehensive screening and therapeutic guidelines for clinicians

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2010.10137.X

National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2010.10137.X

Extensively drug-resistant tuberculosis (XDR-TB) raises challenges in TB control in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2010.10137.X

QuantiFERON-TB Gold testing for tuberculosis in psoriasis patients commencing anti-tumour necrosis factor alpha therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2010.10137.X

Tuberculosis in the age of biologic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2010.10137.X

Attenuated response to purified protein derivative in patients with rheumatoid arthritis: study in a population with a high prevalence of tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2010.10137.X

Decrease in Mycobacterium tuberculosis specific immune responses in patients with untreated psoriasis living in a tuberculosis endemic area.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2010.10137.X

Tuberculin skin test overestimates tuberculosis hypersensitivity in adult patients with psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2010.10137.X

Clinical utility of interferon gamma assay in the diagnosis of tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2010.10137.X

Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2010.10137.X

Tuberculosis screening in patients with psoriasis before antitumour necrosis factor therapy: comparison of an interferon-gamma release assay vs. tuberculin skin test

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2010.10137.X

Comparison of in vitro-specific blood tests with tuberculin skin test for diagnosis of latent tuberculosis before anti-TNF therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2010.10137.X

Routine hospital use of a new commercial whole blood interferon-gamma assay for the diagnosis of tuberculosis infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2010.10137.X

Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2010.10137.X

Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2010.10137.X

Predictive value of a whole blood IFN-gamma assay for the development of active tuberculosis disease after recent infection with Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2010.10137.X

Should Individuals Who Are Tuberculin Skin Test Negative and Positive to RD1–IFN-γ Assay Receive Preventive Therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2010.10137.X

Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2010.10137.X

Influence of glutathione S-transferase M1 and T1 homozygous null mutations on the risk of antituberculosis drug-induced hepatotoxicity in a Caucasian population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2010.10137.X

Genetic polymorphisms of drug-metabolizing enzymes and the susceptibility to antituberculosis drug-induced liver injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2010.10137.X

Extensively drug-resistant Mycobacterium tuberculosis during a trend of decreasing drug resistance from 2000 through 2006 at a Medical Center in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2010.10137.X

Tuberculosis associated with therapy against tumor necrosis factor alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2010.10137.X

Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2010.10137.X

Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2010.10137.X

Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2010.10137.X

BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2010.10137.X

French guidelines for diagnosis and treating latent and active tuberculosis in patients with RA treated with TNF blockers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2010.10137.X

Dynamic Antigen-specific T-Cell Responses after Point-Source Exposure toMycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2010.10137.X

10.1111/J.1365-2133.2010.10137.X

21 January 2018

Identifiers

DOI

1 reference

23 August 2017

1 reference